Literature DB >> 2688213

Is there a case for PAF antagonists in the treatment of ischemic states?

P Braquet, M Paubert-Braquet, M Koltai, R Bourgain, F Bussolino, D Hosford.   

Abstract

It is becoming clear that PAF plays an important role in a variety of life-threatening pathologies including shock, asthma, graft rejection and ischemia-induced damage. Pierre Braquet and colleagues analyse recent reports on PAF and ischemia and propose a hypothesis based on the catastrophe theory to explain why PAF antagonists are effective in countering ischemic injury and many other disorders. PAF antagonists, perhaps in combination with other agents, may consequently prove to have extensive therapeutic potential.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2688213     DOI： 10.1016/0165-6147(89)90103-x

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  13 in total

Review 1.  Fos-jun and the primary genomic response in the nervous system. Possible physiological role and pathophysiological significance.

Authors:  J P Doucet; S P Squinto; N G Bazan
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  Activities of enzymes involved in the metabolism of platelet-activating factor in neural cell cultures during proliferation and differentiation.

Authors:  E Francescangeli; D Lang; H Dreyfus; A Boila; L Freysz; G Goracci
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

Review 3.  Hypoxia and inflammatory synovitis: observations and speculation.

Authors:  C R Stevens; R B Williams; A J Farrell; D R Blake
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

Review 4.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

5.  Pooling of blood in postischemic shock is modulated by platelet-activating factor (PAF).

Authors:  V F Sagach; A V Dmitrieva; P Braquet
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

6.  Molecular and cellular actions of platelet-activating factor in rat heart cells.

Authors:  C V Massey; T A Kohout; S T Gaa; W J Lederer; T B Rogers
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 7.  Platelet-activating factor and the cytokine network in inflammatory processes.

Authors:  B Bonavida; J M Mencia-Huerta
Journal:  Clin Rev Allergy       Date:  1994

Review 8.  Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

Authors:  P Guinot
Journal:  Clin Rev Allergy       Date:  1994

9.  Nitric oxide modulates vascular permeability in the rat coronary circulation.

Authors:  J G Filep; E Földes-Filep; P Sirois
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

10.  Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus.

Authors:  C M Lee; L M Jiang; H S Shang; P M Hon; Y He; H N Wong
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.